COMP <GO>
TXG vs BIO // ENTERPRISE SCALE & MARKET CAP
10x Genomics Inc. (NASDAQ) VS. Bio-Rad Laboratories Inc. (NYSE) • 15-METRIC TALLY: TXG 5
— BIO 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: BIO
LAST: $61.63 (-12.09%) • MKT CAP: $9.13B
market-cap
$9.13B
LAST: $366.16 (-1.62%) • MKT CAP: $9.95B
market-cap
$9.95B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. BIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXG | BIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | 51.90% | +17.20 | TXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -5.70% | 0.50% | -6.20 | BIO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 60.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | 3.64% | -2.42 | BIO | /fcf-yield <GO> |
| Operating Margin | -9.50% | 1.80% | -11.30 | BIO | /operating-margins <GO> |
| Net Profit Margin | -6.80% | 29.40% | -36.20 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 0.70% | +4.50 | TXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 25.02 | 3.59 | +21.43 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.1 | 50.1 | -5.00 | BIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.04 | +0.11 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 12.6x | +11.40 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $9.13B | $9.95B | -$816.7M | BIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXG REV | BIO REV | TXG GROSS % | BIO GROSS % | TXG FCF | BIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | $2.58B | 69.1% | 51.9% | $130.1M | $374.6M |
| FY 2024 | $610.8M | $2.57B | 67.9% | 53.7% | -$5.7M | $289.6M |
| FY 2023 | $618.7M | $2.67B | — | — | -$43.0M | $254.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
BIO // BETA 1.04